

Amendments to the Claims:

Listing of the Claims:

Claims 1-16 (canceled)

Claim 17 (new): A spontaneously dispersible pharmaceutical composition comprising a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist.

Claim 18 (new): A composition according to claim 17 that includes a carrier medium that comprises a lipophilic component and a surfactant component.

Claim 19 (new): A composition as claimed in claim 18 where the 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist is (4R)-4-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide.

Claim 20 (new): A pharmaceutical composition comprising (4R)-4-[N'-methyl-N'-(3,5-bis(trifluoromethyl)benzoyl)amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide as active agent and a carrier medium comprising a lipophilic component and a surfactant, said composition being in a form that is suitable for oral administration.

Claim 21 (new): A composition as claimed in claim 20 wherein the carrier medium further comprises a hydrophilic component.

Claim 22 (new): A composition as claimed in claim 20 wherein the lipophilic component comprises C₈-C₁₀ fatty acid monoglycerides and diglycerides or a refined glycerol-transesterified corn oil.

Claim 23 (new): A composition as claimed in claim 20 wherein the surfactant comprises a polyethyleneglycol-hydrogenated castor oil.

Claim 24 (new): A composition as claimed in claim 21 wherein the hydrophilic component comprises propylene glycol.

Claim 25 (new): A spontaneously dispersible pharmaceutical composition as claimed in claim 18 that comprises about 0.05 to about 20% by weight of (4R)-4-[N'-methyl-N'-(3,5-bis(trifluoro-methyl-benzoyl)amino)-4-(3,4-dichlorobenzyl)-but-2-enoic acid N-[(R)-epsilon-caprolactam-3-yl]-amide, about 5 to about 85 % by weight of a lipophilic component, about 5 to about 90 % by weight of a surfactant, all weights based on the total composition.

Claim 26 (new): A composition as claimed in claim 25 that further comprises about 5 to about 60 % by weight of a hydrophilic component, that weight based on the total composition.

Claim 27 (new): A composition as claimed in claim 17 in the form of a microemulsion preconcentrate.

Claim 28 (new): A composition as claimed in claim 20 in the form of a microemulsion preconcentrate.

Claim 29 (new): A composition as claimed in claim 17 in the form of a microemulsion.

Claim 30 (new): A composition as claimed in claim 20 in the form of a microemulsion.

Claim 31 (new): A composition as claimed in claim 20 in unit dosage form.

Claim 32 (new): A composition as claimed in claim 20 in soft or hard gelatin encapsulated form.

Claim 33 (new): A method of treating a subject suffering from a disorder treatable with a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist comprising administering to that subject a therapeutically effective amount of a pharmaceutical composition as claimed in claim 17.

Claim 34 (new): A process for preparing a spontaneously dispersible pharmaceutical composition containing a 5-aryl-4(R)-arylcarbonylamino-pent-2-enoic acid amide substance P antagonist as an active agent, which process comprises bringing the active agent and a carrier medium comprising a lipophilic component and a surfactant into intimate admixture.

Claim 35 (new): A process for the preparing a microemulsion containing a 5-aryl-4(R)-arylcarbonyl-amino-pent-2-enoic acid amide substance P antagonist as an active agent, which process comprises the steps of:

- (i) bringing the active agent and a carrier comprising (1) a lipophilic component, (2) a surfactant, and (3) a hydrophilic component into intimate admixture to form a spontaneously dispersible pharmaceutical composition; and
- (ii) diluting the spontaneously dispersible pharmaceutical composition in an aqueous medium to form the microemulsion.